Companies · Biotechnology

Tmunity Therapeutics, Inc.

PHILADELPHIA · Biotechnology

Diligence memoA one-page analyst read on Tmunity Therapeutics, Inc. — recommendation, valuation, rhythm, risks.
$175.0M
Total raised · real
5
Rounds
1.5×
Latest step-up
Top 5%
Sector rank · raised
Series C
Latest stage · inferred · Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Tmunity Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.58× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Tmunity Therapeutics, Inc. is one of 4293 Biotechnology companies tracked from PHILADELPHIA. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2015
Year incorporated
2019-10-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2015-12-08 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2015Series A · 2016-01-29 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2016Series A · 2017-12-20 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2017Series C · 2018-01-22 Raised $85M (real) Modeled valuation $3.5B (est)$85M$3.5BSeries C2018Series C · 2018-01-22 Raised $50M (real) Modeled valuation $2.0B (est)$50M$2.0BSeries C2018Series C · 2019-10-22 Raised $75M (real) Modeled valuation $3.1B (est)$75M$3.1BSeries C2019+$5.0M+$5.0M+$85M+$50M+$75MCumulative $225M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2015
Series A extension$5.0M · 2016
Series A extension$5.0M · 2017
Series C$85.0M · 2018no Series B on file
Series C extension$50.0M · 2018
Series C extension$75.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$3.1B
Base estimate est.
$232.0M
Conservative case
$8.1B
Upside case
$500.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $180.8M · 2015-12-082015Series A · modeled $180.8M · 2016-01-29Series A · modeled $180.8M · 2017-12-20Series C · modeled $3.5B · 2018-01-22Series C · modeled $2.0B · 2018-01-22Series C · modeled $3.1B · 2019-10-222019
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
6.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$45.2M/yr
Capital velocity
10.6 yr
On record since
2015
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 24× above median
This company$175.0M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.6× above median
This company$75.0M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 48× above median
This company$3.1B
Sector median$64.2M

Raised more than 96% of sector peers (real $). Modeled value above 97% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #22 of 120.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Stem Biotech LLC · Series C Raised $100.0M · modeled $4.1B (est)Kinnate Biopharma Inc. · Series C Raised $172.5M · modeled $3.9B (est)Arcutis Biotherapeutics, Inc. · Series C Raised $94.5M · modeled $3.9B (est)DNA Research INST LLC · Series C Raised $94.5M · modeled $3.7B (est)M3 Biotechnology, Inc. · Series C Raised $107.3M · modeled $3.6B (est)Checkmate Pharmaceuticals, Inc. · Series C Raised $185.1M · modeled $3.5B (est)Black Diamond Therapeutics, Inc. · Series C Raised $146.3M · modeled $3.5B (est)Finch Therapeutics Group, Inc. · Series C Raised $179.9M · modeled $3.5B (est)Shattuck Labs, Inc. · Series C Raised $165.4M · modeled $3.4B (est)TScan Therapeutics, Inc. · Series C Raised $123.3M · modeled $3.3B (est)Edgewise Therapeutics, Inc. · Series C Raised $120.1M · modeled $3.3B (est)Miragen Therapeutics, Inc. · Series C Raised $197.8M · modeled $3.3B (est)Tmunity Therapeutics, Inc. (this company) Raised $175.0M · modeled $3.1B (est)Tmunity Therapeutics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Stem Biotech LLCSeries C$100.0M$4.1B2.11×
Kinnate Biopharma Inc.Series C$172.5M$3.9B2.02×
Arcutis Biotherapeutics, Inc.Series C$94.5M$3.9B1.99×
DNA Research INST LLCSeries C$94.5M$3.7B1.88×
M3 Biotechnology, Inc.Series C$107.3M$3.6B1.88×
Checkmate Pharmaceuticals, Inc.Series C$185.1M$3.5B1.79×
Black Diamond Therapeutics, Inc.Series C$146.3M$3.5B1.79×
Finch Therapeutics Group, Inc.Series C$179.9M$3.5B1.78×
Shattuck Labs, Inc.Series C$165.4M$3.4B1.75×
TScan Therapeutics, Inc.Series C$123.3M$3.3B1.72×
Edgewise Therapeutics, Inc.Series C$120.1M$3.3B1.70×
Miragen Therapeutics, Inc.Series C$197.8M$3.3B1.69×
Tmunity Therapeutics, Inc. this companySeries C$175.0M$3.1B1.58×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2015-12-08$22.7M$180.8M85%
Series A$5.0M2016-01-29$22.7M$180.8M85%
Series A$5.0M2017-12-20$22.7M$180.8M90%
Series C$85.0M2018-01-22$566.7M$3.5B90%
Series C$50.0M2018-01-22$333.3M$2.0B90%
Series C$75.0M2019-10-22$500.0M$3.1B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2015-12-08
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series A$5.0M2016-01-29
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  3. Series A$5.0M2017-12-20
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  4. Series C$85.0M2018-01-22
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 17.0× larger than the prior — scaling up.
    • 5 investors on this round.
  5. Series C$50.0M2018-01-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  6. Series C$75.0M2019-10-22
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 7 investors on this round.
Intelligence
2020 ~Q3
Modeled next raise · ~9mo cadence
$112.5M
Modeled next size est.range $75.0M$180.0M
1.5×
Last step-up
$45.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Beth Seidenberg14 other2019-10
Patrick Gray9 other2019-10
Sean Parker9 other2018-01
Judith Li7 other2018-01
Yan Zhang3 other2019-10
Garry Nicholson2 other2019-10
Kevin Mahoney2 other2016-01
ALESSANDRO RIVA2018-01
Anne Chew2015-12
CHRISTINA COUGHLIN2019-10
GRAEME BELL2019-10
JASON KRENTZ2019-10
JIANG ZHANG2018-01
MICHAEL CHRISTIANO2017-12
MOJI JAMES2019-10
USMAN AZAM2017-12
Registry & provenance

Tmunity Therapeutics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1661702
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
E-scape Bio, Inc.BiotechnologySeries C$167.1M$2.8Bnetwork1 shared operator · same sector · same stage
Sagimet Biosciences Inc.BiotechnologySeries C$166.6M$2.4Bnetwork1 shared operator · same sector · same stage
Avenzo Therapeutics, Inc.BiotechnologySeries D+$270.6M$355.7Mnetwork2 shared operators · same sector
NextCure, Inc.BiotechnologySeries C$129.9M$113.9Mnetwork1 shared operator · same sector · same stage
Hycor Holdings Inc.BiotechnologySeries C$109.6M$210.8Mnetwork1 shared operator · same sector · same stage
Gritstone bio, Inc.BiotechnologySeries C$100.0M$763.5Mnetwork1 shared operator · same sector · same stage
Arsenal Biosciences, Inc.BiotechnologySeries D+$579.2M$3.5Bnetwork2 shared operators · same sector
Vera Therapeutics, Inc.BiotechnologySeries C$70.7M$2.6Bnetwork1 shared operator · same sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Immune Therapeutics, Inc.BiotechnologySeries A$63.6M90%
Immunomic Therapeutics, Inc.BiotechnologySeries C$41.0M89%
CytoImmune Therapeutics, Inc.BiotechnologySeries B$921.0M88%
ImmunoMolecular Therapeutics, Inc.BiotechnologySeries A$215.8M88%
Immunomet Therapeutics, Inc.BiotechnologyPre-Seed$1.5M87%
Immunitas Therapeutics, Inc.BiotechnologySeries B$717.5M86%
ImmuneSensor Therapeutics, Inc.BiotechnologySeries A$114.6M85%
Telo Therapeutics, Inc.BiotechnologySeries A$108.3M85%
Frequently asked
How much funding has Tmunity Therapeutics, Inc. raised?
Tmunity Therapeutics, Inc. has raised approximately $175.0M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Tmunity Therapeutics, Inc.'s estimated valuation?
Provath's modeled valuation for Tmunity Therapeutics, Inc. is approximately $3.1B (modeled range $232.0M–$8.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Tmunity Therapeutics, Inc. at?
Tmunity Therapeutics, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Tue Oct 22.
What does Tmunity Therapeutics, Inc. do and where is it based?
Tmunity Therapeutics, Inc. operates in the Biotechnology sector, based in PHILADELPHIA.
Explore related

See where Tmunity Therapeutics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Tmunity Therapeutics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.